Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL
Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL
The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab lengthens the time a patient remains free of leukemia symptoms.
Inclusion Criteria:
Exclusion Criteria:
Fresno, California 93720, United States
Ottawa, Ontario K1H 1C4, Canada
Toronto, Ontario M5G 2M9, Canada
Debrecen, 4032, Hungary
Bari, Apulia 70124, Italy
San Giovanni Rotondo, Apulia 71013, Italy
Naples, Campania 80131, Italy
Rome, Lazio 00161, Italy
Milan, Lombardy 20162, Italy
Auckland, 1023, New Zealand
Lublin, 20-081, Poland
Warsaw, 00-957, Poland
Târgu Mureş, 540136, Romania
Moscow, 115478, Russia
Obninsk, 249036, Russia
Saint Petersburg, 193024, Russia
Saint Petersburg, 194291, Russia
Saint Petersburg, 197110, Russia